Opening the brain’s secret back door: A conversation with Synchron co-founder and CEO Dr. Tom Oxley
How Recor Medical won the renal denervation race for FDA approval
Medtech’s biggest personnel moves of 2023Leadership and innovation in medtech
Creativity, energy, agility — those are three words Recor Medical CEO Lara Barghout used to describe the culture at the world’s first device developer to win FDA approval for hypertension-treating renal denervation (RDN).
You can add persistence to that list. Ever since its founding in 2009, Recor Medical and its team has been pushing to deliver a safe and effective RDN system. The seemingly long odds got longer as larger competitors pulled the plug on their own programs — or in Medtronic’s case, pushed on despite clinical trial failures and won approval shortly after Recor.
Our annual Leadership in Medtech issue of Medical Design &a…